Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin

28 May 2025

Abstract excerpt

ABSTRACT: Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with high efficacy in lymphoid malignancies. It targets the B-cell surface protein CD22, which is expressed in most B-cell acute lymphoblastic leukemia (B-ALL) cases, albeit with variable intensity. However, factors governing CD22 expression and thus leukemia sensitivity to InO remain incompletely understood. Using multiomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lymphoma Diagnosis and Treatment
Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40435412
DOI: 10.1182/blood.2024028215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicinPMID 40435412Read ↗

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.Semantic proximity Read ↗

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLSemantic proximity Read ↗

PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemiaSemantic proximity Read ↗

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Case Report: Immune-driven clonal selection underlying lineage switch from B-Precursor acute lymphoblastic leukemia to acute myeloid leukemia following inotuzumab ozogamicin.Semantic proximity Read ↗

Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemiaSemantic proximity Read ↗

A multi-omic single-cell landscape reveals transcription and epigenetic regulatory features of t(8;21) AMLSemantic proximity Read ↗

Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Aberrant ZNF423 impedes B cell differentiation and is linked to adverse outcome of <i>ETV6-RUNX1</i> negative B precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Single-cell genomics links CAR architectures to in vivo effector chromatin states in T cells responding to antigen-low leukemiaSemantic proximity Read ↗

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.Semantic proximity Read ↗

Epigenetic silencing of transposable elements by IRF2BP2 is a selective dependency of myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.